Varenicline vs. Combination NRT vs. Bupropion as First-Line Smoking Cessation
A motivated patient wants a direct recommendation, not a menu — and is nervous about a varenicline safety warning that was formally removed years ago after the very trial that answers her question.
G.H. is due to become a grandmother for the first time in four months, and told her daughter recently that she wants to hold her granddaughter without smelling like cigarette smoke and without a cough interrupting every other sentence. She is fifty-eight, has worked as a school librarian for over two decades — a job she loves partly because it's kept her mostly away from the break-room culture that made quitting harder at her previous workplace — and has smoked roughly a pack a day since her early twenties. She has quit twice before for a few months each time, using nicotine patches alone, and relapsed both times during periods of high stress at work that she can name specifically, even now.
She has well-controlled hypertension and no seizure history, no psychiatric hospitalization, though she mentions a period of depression in her thirties that resolved without ongoing treatment and that she brings up carefully, watching for a reaction. She has read online that varenicline carried a boxed warning for years over neuropsychiatric side effects and is nervous about that history, even though she also read the warning was later removed after further study found the risk wasn't borne out. She wants to understand plainly which of the three main options actually gives her the best real chance this time, given that patches alone failed her twice already, both times under circumstances she can describe in specific detail. Her daughter, who quit smoking herself two years ago using varenicline without any issues, has been gently encouraging her to ask about it directly, which is part of why she finally has, four months out from a due date she's already counting down.
The most effective option, and the one she's actually afraid of, aren't the same conversation
Based on the comparative evidence, I'd recommend varenicline first. The EAGLES trial — a large randomized study run at the FDA's and EMA's own request specifically to settle the safety question — found varenicline more effective than placebo, nicotine patch, and bupropion for sustained abstinence, and did not find a significant increase in neuropsychiatric adverse events compared to patch or placebo. That finding is exactly what led to the boxed warning being removed.
I'd want to make sure she understands why patch monotherapy specifically failed her twice before we move past nicotine replacement entirely: a steady-state patch doesn't cover acute breakthrough cravings during stress, which is exactly when she relapsed both times. Combination NRT — patch plus a faster-acting gum or lozenge for those moments — is a genuinely different approach, not simply repeating what already failed her.
That's a real point, but EAGLES also directly compared varenicline against nicotine patch and found it more effective overall — combination NRT's specific advantage over patch alone doesn't automatically close the efficacy gap with varenicline shown in that trial.
Both of you are right about the data, but I want to bring in what she actually told us: she's anxious about varenicline specifically, and she has a resolved depressive history that makes that anxiety understandable even though EAGLES' data doesn't support it being a special risk for her. A medication she's uneasy about is one she may not take consistently for months, regardless of how it performed in a trial. I'd walk her through the EAGLES findings directly, answer her specific fear plainly, and let her make an informed choice between varenicline and combination NRT rather than picking for her.
Agreed: G.H. was walked through the EAGLES findings directly, including the reassuring safety data, and chose varenicline herself once her specific fear was addressed plainly rather than dismissed.
Not agreed: whether every patient with a resolved, non-recurrent psychiatric history and no current symptoms should receive this same level of individualized safety discussion before starting varenicline, or whether that risks over-emphasizing a risk EAGLES itself found not to be elevated. The primary care physician sees it as good practice regardless of trial findings; the addiction psychiatrist worried that routinely raising it could inadvertently reinforce the same outdated fear the trial was designed to resolve.